Literature DB >> 8613550

Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury.

T P Shanley1, J L Peters, M L Jones, S W Chensue, S L Kunkel, P A Ward.   

Abstract

IL-1 receptor antagonist (IL-1Ra) has regulatory effects on IL-1 activity both in vitro and in vivo. In the IgG immune complex model of lung injury in rats, exogenously administered human IL-1Ra suppressed neutrophil recruitment and ensuing lung injury. In this study, we sought to determine if endogenous rat IL-1Ra might regulate this lung-inflammatory response. By Northern blot analysis of lung mRNA and Western analysis of bronchoalveolar lavage (BAL) fluids, rat IL-1Ra expression was found to increase during development of inflammation in IgG immune complex-mediated alveolitis. By immunostaining, alveolar macrophages and recruited neutrophils were the apparent sources of IL-1Ra. In vivo blocking of endogenous IL-1Ra resulted in a 53% increase in lung vascular permeability and a 180% increase in BAL fluid neutrophils. In companion studies, a significant increase in IL-1beta was found, whereas no significant change in TNF-alpha activity was observed. Whereas the in vivo regulatory effects of IL-1R appear to be limited to IL-1beta, IL-10 regulates both IL-1beta and TNF-alpha in this model, reflected by a 48% increase in BAL IL-1beta in rats treated with anti-IL-10. These findings suggest that IL-1Ra is an intrinsic regulator of inflammatory injury after deposition of IgG immune complexes and that it regulates production of IL-1beta.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8613550      PMCID: PMC507142          DOI: 10.1172/JCI118520

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  49 in total

1.  Expression and regulation of human alveolar macrophage-derived interleukin-1 receptor antagonist.

Authors:  S A Moore; R M Strieter; M W Rolfe; T J Standiford; M D Burdick; S L Kunkel
Journal:  Am J Respir Cell Mol Biol       Date:  1992-06       Impact factor: 6.914

2.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

Authors:  E Fischer; M A Marano; K J Van Zee; C S Rock; A S Hawes; W A Thompson; L DeForge; J S Kenney; D G Remick; D C Bloedow
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

3.  Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease.

Authors:  E Fischer; K J Van Zee; M A Marano; C S Rock; J S Kenney; D D Poutsiaka; C A Dinarello; S F Lowry; L L Moldawer
Journal:  Blood       Date:  1992-05-01       Impact factor: 22.113

4.  Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis.

Authors:  F Cominelli; C C Nast; A Duchini; M Lee
Journal:  Gastroenterology       Date:  1992-07       Impact factor: 22.682

5.  Endogenous IL-1 receptor antagonist protein (IRAP) regulates schistosome egg granuloma formation and the regional lymphoid response.

Authors:  S W Chensue; M Bienkowski; T E Eessalu; K S Warmington; S D Hershey; N W Lukacs; S L Kunkel
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

6.  Regulation of interleukin-1ra, interleukin-1 alpha, and interleukin-1 beta production by human alveolar macrophages with phorbol myristate acetate, lipopolysaccharide, and interleukin-4.

Authors:  B Galve-de Rochemonteix; L P Nicod; R Chicheportiche; S Lacraz; C Baumberger; J M Dayer
Journal:  Am J Respir Cell Mol Biol       Date:  1993-02       Impact factor: 6.914

7.  Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1.

Authors:  M S Mulligan; P A Ward
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

8.  IL-1 receptor antagonist release is regulated differently in human alveolar macrophages than in monocytes.

Authors:  J N Kline; M M Monick; G W Hunninghake
Journal:  J Appl Physiol (1985)       Date:  1992-10

9.  Protective effects of IL-4 and IL-10 against immune complex-induced lung injury.

Authors:  M S Mulligan; M L Jones; A A Vaporciyan; M C Howard; P A Ward
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

10.  Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils.

Authors:  M Malyak; R E Swaney; W P Arend
Journal:  Arthritis Rheum       Date:  1993-06
View more
  5 in total

Review 1.  Hypersensitivity pneumonitis in children: clinical features, diagnosis, and treatment.

Authors:  Purnima Venkatesh; Laurianne Wild
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Persistent neutrophil dysfunction and suppression of acute lung injury in mice following cecal ligation and puncture sepsis.

Authors:  Jamison J Grailer; Miriam Kalbitz; Firas S Zetoune; Peter A Ward
Journal:  J Innate Immun       Date:  2014-05-23       Impact factor: 7.349

Review 3.  Biological role of interleukin 1 receptor antagonist isoforms.

Authors:  W P Arend; C J Guthridge
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

4.  In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13.

Authors:  A B Lentsch; T P Shanley; V Sarma; P A Ward
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

5.  Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors.

Authors:  R Clynes; J S Maizes; R Guinamard; M Ono; T Takai; J V Ravetch
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.